Source-grounded facts extracted from CytoDyn Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CytoDyn Inc. amended a notes offering (effective 2026-03-24).
“On March 24, 2026, the Company and the holders of Note 1 and Note 2 (collectively, the “Noteholders”) agreed to extend the maturity date of each of the Notes by 36 months (the “Extension Periods”).”
CytoDyn Inc.: Amended certificate of incorporation to increase authorized shares of common stock from 1,750,000,000 to 2,250,000,000 (effective 2025-11-21).
“On November 21, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to its Certificate of Incorporation, increasing the total number of authorized shares of common stock, par value $0.001 per share, from 1,750,000,000 to 2,250,000,000.”
Robert E. Hoffman was appointed as Chief Financial Officer at CytoDyn Inc..
“On May 2, 2025, the Company entered into an agreement with Robert E. Hoffman (“Mr. Hoffman”), under which Mr. Hoffman will serve as the Company’s Chief Financial Officer (“CFO”), effective May 15, 2025 (the “Employment Agreement”).”
CytoDyn Inc. dismissed BF Borgers CPA PC as its auditor.
“On May 6, 2024, CytoDyn Inc. (the “Company”), at the direction of the Audit Committee of the Company’s Board of Directors (the “Audit Committee”), dismissed BF Borgers CPA PC (“BF Borgers”) as the Company’s independent registered public accounting firm.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.